Physiological roles of peroxido-vanadium complexes: Leitmotif as their signal transduction pathway.

Evidence exists that supports the various physiological roles of vanadium compounds, although the amount of vanadium in our body is limited. This limited concentration in our body does not attract much attention of the biological chemists, although the fact is present; even in the 19th century, vanadium derivatives were used for the therapeutic reagents. In the middle of the 20th century, the main focus of vanadium chemistry is mainly on the chemical and material fields. After the first discovery of vanadium compounds expressing ATPase activity, oxidovanadium(IV) sulfate was reported to have insulin mimic activity. Additionally, because some vanadium compounds possess cellular toxicity, trials were also carried out to examine the possible use of vanadium compounds as cancer therapeutics. The application of vanadium complexes was extended in recent years especially in the 21st century. In this review, we briefly explain the historical background of vanadium chemistry and also summarize the physiological role of vanadium complexes mainly focusing on the synthesis and physiological role of peroxidovanadium compounds and their interactions with insulin signal transduction pathways.

Regulation of the physiological effects of peroxidovanadium(V) complexes by the electronic nature of ligands.

Although the physiological effects of peroxidovanadium(V) complexes (pVs) have been extensively investigated both in vitro and in vivo with regard to their pharmacological activity, such as insulin-mimetic and antitumor activities, the relationship between the chemical and pharmacological properties of pVs is still unclear. Rational drug design with pVs depends on a full understanding of this relationship. Toward this end, the current report evaluates the physiological effects of 13 pVs were evaluated bound to a variety of ligand. Six of these ligands are tripodal tetradentate ligands, one is a linear tetradentate ligand, one boasts two pendant groups, three are tridentate ligands, and two are alkoxido-bridging, dinucleating ligands. The cytotoxicities of these pVs could be classified into three groups: significantly toxic, moderately toxic, and non- or negligibly toxic. Further, IC50 values could be related with the LMCT transition energies of the peroxido group, particularly among complexes with similar ligands. This relation indicates that the electronic properties of the peroxido group affected the physiological activity of the pV complex. We also investigated the insulin-signaling intensity of each pV. Phosphorylation of protein kinase B and extracellular signal-regulated kinase 1/2, two major insulin-signaling proteins, was observed after treating cells with pV for 30 min. Phosphorylation was particularly remarkable for complexes that exhibited high cytotoxicity. The present results demonstrate that the toxicity and physiological effects of pVs can be controlled by selecting an appropriate ancillary ligand. These findings provide a guide for synthesis of new pVs that may be used as candidate therapeutic agents.

Preparation, structure, and properties of tetranuclear vanadium(III) and (IV) complexes bridged by diphenyl phosphate or phosphate.

Three novel tetranuclear vanadium(III) or (IV) complexes bridged by diphenyl phosphate or phosphate were prepared and their structures characterized by X-ray crystallography. The novel complexes are [{V(III)(2)(µ-hpnbpda)}(2){µ-(C(6)H(5)O)(2)PO(2)}(2)(µ-O)(2)]·6CH(3)OH (1), [{V(III)(2)(µ-tphpn)(µ-η(3)-HPO(4))}(2)(µ-η(4)-PO(4))](ClO(4))(3)·4.5H(2)O (2), and [{(V(IV)O)(2)(µ-tphpn)}(2)(µ-η(4)-PO(4))](ClO(4))(3)·H(2)O (3), where hpnbpda and tphpn are alkoxo-bridging dinucleating ligands. H(3)hpnbpda represents 2-hydroxypropane-1,3-diamino-N,N'-bis(2-pyridylmethyl)-N,N'-diacetic acid, and Htphpn represents N,N,N',N'-tetrakis(2-pyridylmethyl)-2-hydroxy-1,3-propanediamine. A dinuclear vanadium(IV) complex without a phosphate bridge, [(VO)(2)(µ-tphpn)(H(2)O)(2)](ClO(4))(3)·2H(2)O (4), was also prepared and structurally characterized for comparison. The vanadium(III) center in 1 adopts a hexacoordinate structure while that in 2 adopts a heptacoordinate structure. In 1, the two dinuclear vanadium(III) units bridged by the alkoxo group of hpnbpda are further linked by two diphenylphosphato and two oxo groups, resulting in a dimer-of-dimers. In 2, the two vanadium(III) units bridged by tphpn are further bridged by three phosphate ions with two different coordination modes. Complex 2 is oxidized in aerobic solution to yield complex 3, in which two of the three phosphate groups in 2 are substituted by oxo groups.

A novel vanadium reductase, Vanabin2, forms a possible cascade involved in electron transfer.

The unusual ascidian ability to accumulate high levels of vanadium ions at concentrations of up to 350 mM, a 10(7)-fold increase over that found in seawater, has been attracting interdisciplinary attention for a century. Accumulated V(V) is finally reduced to V(III) via V(IV) in ascidian vanadocytes. Reducing agents must therefore participate in the reduction. Previously, we identified a vanadium-binding protein, Vanabin2, in which all 18 cysteines form nine disulfide bonds. Here, we report that Vanabin2 is a novel vanadium reductase because partial cleavage of its disulfide bonds results in the reduction of V(V) to V(IV). We propose that Vanabin2 forms a possible electron transfer cascade from the electron donor, NADPH, via glutathione reductase, glutathione, and Vanabin2 to the acceptor, and vanadium ions conjugated through thiol-disulfide exchange reactions.

Identification and biochemical analysis of a homolog of a sulfate transporter from a vanadium-rich ascidian Ascidia sydneiensis samea.

BACKGROUND: Several species of ascidians accumulate extremely high levels of vanadium ions in the vacuoles of their blood cells (vanadocytes). The vacuoles of vanadocytes also contain many protons and sulfate ions. To maintain the concentration of sulfate ions, an active transporter must exist in the blood cells, but no such transporter has been reported in vanadium-accumulating ascidians. METHODS: We determined the concentration of vanadium and sulfate ions in the blood cells (except for the giant cells) of Ascidia sydneiensis samea. We cloned cDNA for an Slc13-type sulfate transporter, AsSUL1, expressed in the vanadocytes of A. sydneiensis samea. The synthetic mRNA of AsSUL1 was introduced into Xenopus oocytes, and its ability to transport sulfate ions was analyzed. RESULTS: The concentrations of vanadium and sulfate ions in the blood cells (except for the giant cells) were 38 mM and 86 mM, respectively. The concentration of sulfate ions in the blood plasma was 25 mM. The transport activity of AsSUL1 was dependent on sodium ions, and its maximum velocity and apparent affinity were 2500 pmol/oocyte/h and 1.75 mM, respectively. GENERAL SIGNIFICANCE: This could account for active uptake of sulfate ions from blood plasma where sulfate concentration is 25 mM, as determined in this study.

Reduction of vanadium(V) to vanadium(IV) by NADPH, and vanadium(IV) to vanadium(III) by cysteine methyl ester in the presence of biologically relevant ligands.

To better understand the mechanism of vanadium reduction in ascidians, we examined the reduction of vanadium(V) to vanadium(IV) by NADPH and the reduction of vanadium(IV) to vanadium(III) by L-cysteine methyl ester (CysME). UV-vis and electron paramagnetic resonance spectroscopic studies indicated that in the presence of several biologically relevant ligands vanadium(V) and vanadium(IV) were reduced by NADPH and CysME, respectively. Specifically, NADPH directly reduced vanadium(V) to vanadium(IV) with the assistance of ligands that have a formation constant with vanadium(IV) of greater than 7. Also, glycylhistidine and glycylaspartic acid were found to assist the reduction of vanadium(IV) to vanadium(III) by CysME.

Mononuclear and dinuclear monoperoxovanadium(v) complexes with a hetero ligand. 1.(1) Self-decomposition reaction, detection of reactive oxygen species, and oxidizing ability.

A mononuclear peroxovanadium(V) complex with histamine-N,N-diacetate (histada), K[VO(O(2))(histada)], and a dinuclear peroxovanadium(V) complex with 2-oxo-1,3-diaminopropane-N,N,N',N'-tetraacetate (dpot), Cs(3)[(VO)(2)(O(2))(2)(dpot)], were prepared and characterized. The self-decomposition reaction was examined for these peroxovanadium(V) complexes as well as for K[VO(O(2))(cmhist)] (cmhist = N-carboxymethylhistidinate). The reaction profiles depicted by the absorbance change in the UV-vis spectrum show a sigmoid shape with an induction period. The induction period is reduced by the addition of acid, fluoride, thiocyanate, VO(2+), VO(2)(+), and trolox compared to the solution containing perchlorate. On the other hand, the induction period was elongated by the addition of chloride, bromide, and 2-tert-butyl-p-cresol. These behaviors are discussed on the basis of a radical chain mechanism. The self-decomposition reactions have also been followed by the (1)H and (51)V NMR and EPR spectra. These spectral studies as well as the UV-vis spectral study indicate that vanadium(V) is partly reduced to vanadium(IV) in the self-decomposition process. The histada complex yields a mixed-valence dinuclear complex in a concentrated solution, and the dpot complex yields a mixed-valence tetranuclear complex. The reduction of vanadium ion suggests that the peroxo ligand may act as a reducing agent. In order to know the fate of the peroxo ligand, we tried to detect superoxide anion and hydroxyl radical, which were anticipated to be produced in the self-decomposition process. The formation of superoxide anion was spectrophotometrically confirmed using two independent methods, including the reduction of cytochrome c and the reduction of sodium 4-[3-(iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1). The formation of hydroxyl radical was confirmed by an EPR spin trapping technique. The oxidizing abilities of the peroxovanadium(V) complexes toward bovine serum albumin (BSA) were also evaluated. In the protein carbonyl assay, it was found that the total amount of protein carbonyl in BSA was increased by the reaction with the peroxovanadium complexes in the concentration-dependent manner. In addition, the oxidation of sulfhydryl group in BSA induced by the peroxovanadium complexes was confirmed.

Aerobic oxidation of thiols to disulfides catalyzed by trichlorooxyvanadium.

Thiols were converted into disulfide by the aerobic oxidation catalyzed by trichlorooxyvanadium in the presence of molecular sieves 3A.

Vanadium-binding proteins (vanabins) from a vanadium-rich ascidian Ascidia sydneiensis samea.

Since the beginning of the last century, it has been known that ascidians accumulate high levels of a transition metal, vanadium, in their blood cells, although the mechanism for this curious biological function remains unknown. Recently, we identified three vanadium-binding proteins (vanabins), previously denoted as vanadium-associated proteins (VAPs) [Zool. Sci. 14 (1997) 37], from the cytoplasm fraction of vanadium-containing blood cells (vanadocytes) of the vanadium-rich ascidian Ascidia sydneiensis samea. Here, we describe the cloning, expression, and analysis of the metal-binding ability of vanabins. Recombinant proteins of two independent but related vanabins, vanabin1 and vanabin2, bound to 10 and 20 vanadium(IV) ions with dissociation constants of 2.1x10(-5) and 2.3x10(-5) M, respectively. The binding of vanadium(IV) to these vanabins was inhibited by the addition of copper(II) ions, but not by magnesium(II) or molybdate(VI) ions. Vanabins are the first proteins reported to show specific binding to vanadium ions; this should provide a clue to resolving the problem regarding the selective accumulation of vanadium in ascidians.

Vanadocytes, cells hold the key to resolving the highly selective accumulation and reduction of vanadium in ascidians.

Since Henze discovered vanadium in the blood (or coelomic) cells of an ascidian in 1911, this unusual phenomenon has attracted the interest of many investigators. The highest concentration of vanadium (350 mM) in the blood cells of Ascidia gemmata, which belongs to the suborder Phlebobranchia, is 10(7) times higher than that in seawater. Of the approximately 10 types of blood cells, a combination of cell fractionation and neutron-activation analysis revealed that the signet ring cells were the true vanadocytes. In the vanadocytes, 97.6% of the vanadium is in the +3 oxidation state (III). The extremely low pH of 1.9 found in vanadocytes suggests that protons, concentrated by an H(+)-ATPase, might be linked to the accumulation of vanadium energetically. The antigen recognized by a monoclonal antibody, S4D5, prepared to identify vanadocytes, was determined to be 6-PGDH in the pentose phosphate pathway. NADPH produced in the pentose phosphate pathway in vanadocytes is thought to participate in the reduction of vanadium(V) to vanadium(IV). During embryogenesis, a vanadocyte-specific antigen first appears in the body wall at the same time that significant accumulations of vanadium become apparent. Three different vanadium-associated proteins (VAPs) were extracted from the blood cells of vanadium-rich ascidians. These are 12.5, 15, and 16 kDa in size and are associated with vanadium in an approximate ratio of 1:16. The cDNA encoding the 12.5 and 15 kDa VAPs was isolated and the proteins encoded were found to be novel. Further biochemical and biophysical characterization of the VAPs is in progress.

Synthesis, Magnetic Properties, and Electronic Spectra of Octahedral Mixed-Ligand (beta-Diketonato)nickel(II) Complexes with a Chelated Nitronyl Nitroxide Radical.

Two series of new mixed-ligand nitronyl nitroxide Ni(II) complexes of [Ni(beta-diketonato)(2)(NIT2-py)] and [Ni(beta-diketonato)(tmen)(NIT2-py)](+) types with various kinds of beta-diketonates have been synthesized and structurally and magnetically characterized, where NIT2-py is 2-(2-pyridyl)-4,4,5,5-tetramethyl-4,5-dihydro-1H-imidazolyl-1-oxyl 3-oxide and tmen is N,N,N ',N '-tetramethylethylenediamine. The X-ray structural analysis for three tmen complexes with 2,4-pentanedionate (1b), 1,3-diphenyl-1,3-propanedionate (2b), and 4,4,4-trifluoro-1-phenyl-1,3-butanedionate (5b) demonstrated that the beta-diketonato complexes assume a mer (cis,trans) N(3)O(3) geometrical configuration. The structural parameters are as follows: 1b (C(23)H(39)F(6)N(5)NiPO(4).(1)/(3)CH(2)Cl(2)), trigonal, R&thremacr;, a = 33.299(5) Å, c = 15.007(9) Å, Z = 18; 2b (C(28)H(41)F(6)N(5)NiPO(4)), orthorhombic, Pbca, a = 23.732(6) Å, b = 18.504(5) Å, c = 15.345(4) Å, Z = 8; 5b (C(28)H(38)F(9)N(5)NiPO(4)), triclinic, P&onemacr;, a = 12.068(2) Å, b = 16.942(2) Å, c = 9.161(1) Å, alpha = 105.26(1) degrees, beta = 103.72(1) degrees, gamma = 71.62(1) degrees, Z = 2. The antiferromagnetic interactions between Ni(II) and NIT2-py were found within ranges of J = -207 to -224 cm(-)(1) for the bis(beta-diketonato) complexes and of J = -35 to -150 cm(-)(1) for the (beta-diketonato)(tmen) complexes. The displacement of the beta-diketonates with tmen in bis(beta-diketonato) complexes decreases the J values, and the effect of the 1,3-substituents in the beta-diketonates on the J values is observed in a systematic manner for all the bis(beta-diketonato) complexes and for the (methyl- and phenyl-substituted-beta-diketonato)(tmen) complexes but not for the trifluoromethyl-substituted complex. The room-temperature electronic spectra of the bis(beta-diketonato) and the (beta-diketonato)(tmen) complexes exhibit enhanced spin-forbidden d-d transitions at 13.0 x 10(3) cm(-)(1) and new metal-ligand charge-transfer (MLCT) transitions around (16.0-19.0) x 10(3) cm(-)(1). The variation of the spectroscopic characteristics with modification of the beta-diketonato ligands is discussed through the exchange mechanism in connection with the antiferromagnetic interactions in terms of the substituent effects or the Hammett sigma(m) constants.